Chronic Heart Failure: Focus on Differences Between Men and Women
https://doi.org/10.18087/cardio.2024.11.n2790
Abstract
This review focuses on the sex-related differences of patients in etiological factors, clinical picture, and objective laboratory and instrumental signs of heart failure. The authors performed an analysis of the effectiveness of drug and non-drug treatments depending on the gender of patients with low and preserved left ventricular ejection fraction, which should improve the quality of medical care and outcomes in patients with heart failure.
Supporting agencies: No conflict of interest is reported.
About the Author
M. G. Glezer
Vladimirsky Moscow Region Research Clinical Institute; Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
MD, Professor, Department of Cardiology, Functional and Ultrasound Diagnostics of the Institute of Clinical Medicine named after N.V. Sklifosovskogo
Moscow, Russia
References
1. Drapkina O.M., Boytsov S.A., Omelyanovskiy V.V., Kontsevaya A.V., Loukianov M.M., Ignatieva V.I. et al. Socio-economic impact of heart failure in Russia. Russian Journal of Cardiology. 2021;26(6):81–9. DOI: 10.15829/1560-4071-2021-4490
2. Mohebi R, Chen C, Ibrahim NE, McCarthy CP, Gaggin HK, Singer DE et al. Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates. Journal of the American College of Cardiology. 2022;80(6):565–78. DOI: 10.1016/j.jacc.2022.05.033
3. Lam CSP, Arnott C, Beale AL, Chandramouli C, Hilfiker-Kleiner D, Kaye DM et al. Sex differences in heart failure. European Heart Journal. 2019;40(47):3859–3868c. DOI: 10.1093/eurheartj/ehz835
4. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068–72. DOI: 10.1161/01.cir.0000039105.49749.6f
5. Dunlay SM, Givertz MM, Aguilar D, Allen LA, Chan M, Desai AS et al. Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America: This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019;140(7):e294–324. DOI: 10.1161/CIR.0000000000000691
6. Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Fomin I.V., Badin Yu.V., Polyakov D.S. et al. Veritable prevalence of CHF in the European part of Russian Federation (EPOCHA trial, hospital stage). Russian Heart Failure Journal. 2011;12(2):63–8.
7. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareev V.Yu., Ageev F.T., Artemjeva E.G. et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCHCHF study. Kardiologiia. 2021;61(4):4–14. DOI: 10.18087/cardio.2021.4.n1628
8. Shlyakhto E.V., Belenkov Yu.N., Boytsov S.A., Villevalde S.V., Galyavich A.S., Glezer M.G. et al. Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation ‘PRIORITET-CHF’: initial characteristics and treatment of the first included patients. Russian Journal of Cardiology. 2023;28(10):93–103. DOI: 10.15829/1560-4071-2023-5593
9. Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. 2007;93(9):1137–46. DOI: 10.1136/hrt.2003.025270
10. Coutinho T, Pellikka PA, Bailey KR, Turner ST, Kullo IJ. Sex Differences in the Associations of Hemodynamic Load With Left Ventricular Hypertrophy and Concentric Remodeling. American Journal of Hypertension. 2016;29(1):73–80. DOI: 10.1093/ajh/hpv071
11. Prokofieva E.B., Glezer M.G. Stiffness of the Arterial Wall and Central Hemodynamics During Long-Term Combination Antihypertensive Therapy. Kardiologiia. 2015;55(4):19–24. DOI: 10.18565/cardio.2015.4.19-24
12. Haider AW, Larson MG, Franklin SS, Levy D. Systolic Blood Pressure, Diastolic Blood Pressure, and Pulse Pressure as Predictors of Risk for Congestive Heart Failure in the Framingham Heart Study. Annals of Internal Medicine. 2003;138(1):10–6. DOI: 10.7326/0003-4819-138-1-200301070-00006
13. Glezer M.G. Arterial hypertension in women. Medical Business. 2013;1:33–40.
14. Huang G, Liu X-H, Zhang Y, Zhu Y-X, He Y, Wang T-B et al. Nocturnal hypertension and riser pattern are associated with heart failure rehospitalization in patients with heart failure with preserved ejection fraction. Journal of Geriatric Cardiology. 2023;20(6):448–58. DOI: 10.26599/1671-5411.2023.06.003
15. Guerra S, Leri A, Wang X, Finato N, Di Loreto C, Beltrami CA et al. Myocyte Death in the Failing Human Heart Is Gender Dependent. Circulation Research. 1999;85(9):856–66. DOI: 10.1161/01.RES.85.9.856
16. Alloatti G, Penna C, Comità S, Tullio F, Aragno M, Biasi F et al. Aging, sex and NLRP3 inflammasome in cardiac ischaemic disease. Vascular Pharmacology. 2022;145:107001. DOI: 10.1016/j.vph.2022.107001
17. Van Blokland IV, Groot HE, Hendriks T, Assa S, Van Der Harst P. Sex differences in leukocyte profile in ST-elevation myocardial infarction patients. Scientific Reports. 2020;10(1):6851. DOI: 10.1038/s41598-020-63185-3
18. Cavasin MA, Tao Z, Menon S, Yang X-P. Gender differences in cardiac function during early remodeling after acute myocardial infarction in mice. Life Sciences. 2004;75(18):2181–92. DOI: 10.1016/j.lfs.2004.04.024
19. López-Palop R, Carrillo P, Lozano Í. Impact of Sex in the Incidence of Heart Failure in Patients with Chronic Coronary Syndrome. Current Heart Failure Reports. 2024;21(4):354–66. DOI: 10.1007/s11897-024-00663-z
20. Elia E, Bruno F, Crimi G, Wańha W, Leonardi S, Mauro M et al. Gender differences in the development of heart failure after acute coronary syndrome: Insight from the CORALYS registry. International Journal of Cardiology. 2024;397:131622. DOI: 10.1016/j.ijcard.2023.131622
21. La Vecchia G, Fumarulo I, Caffè A, Chiatto M, Montone RA, Aspromonte N. Microvascular Dysfunction across the Spectrum of Heart Failure Pathology: Pathophysiology, Clinical Features and Therapeutic Implications. International Journal of Molecular Sciences. 2024;25(14):7628. DOI: 10.3390/ijms25147628
22. Shah SJ, Lam CSP, Svedlund S, Saraste A, Hage C, Tan R-S et al. Prevalence and correlates of coronary microvascular dysfunction in heart failure with preserved ejection fraction: PROMIS-HFpEF. European Heart Journal. 2018;39(37):3439–50. DOI: 10.1093/eurheartj/ehy531
23. D’Amario D, Laborante R, Bianchini E, Ciliberti G, Paglianiti DA, Galli M et al. Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta‐analysis. ESC Heart Failure. 2024;11(4):2063–75. DOI: 10.1002/ehf2.14626
24. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology. 2013;62(4):263–71. DOI: 10.1016/j.jacc.2013.02.092
25. Pepine CJ, Anderson RD, Sharaf BL, Reis SE, Smith KM, Handberg EM et al. Coronary Microvascular Reactivity to Adenosine Predicts Adverse Outcome in Women Evaluated for Suspected Ischemia. Journal of the American College of Cardiology. 2010;55(25):2825–32. DOI: 10.1016/j.jacc.2010.01.054
26. Aimo A, Panichella G, Barison A, Maffei S, Cameli M, Coiro S et al. Sex-related differences in ventricular remodeling after myocardial infarction. International Journal of Cardiology. 2021;339:62–9. DOI: 10.1016/j.ijcard.2021.07.036
27. Álvarez-Zaballos S, Martínez-Sellés M. Impact of Sex and Diabetes in Patients with Heart Failure. Current Heart Failure Reports. 2024;21(4):389–95. DOI: 10.1007/s11897-024-00666-w
28. Hofer-Zeni S, Leutner M, Klimek P, Bellach L, Pavo N, Prausmüller S et al. Sex differences in the diagnostic algorithm of screening for heart failure by symptoms and NT-proBNP in patients with type 2 diabetes. Cardiovascular Diabetology. 2024;23(1):280. DOI: 10.1186/s12933-024-02360-6
29. Jiménez A, Vlacho B, Mata-Cases M, Real J, Mauricio D, Franch-Nadal J et al. Sex and age significantly modulate cardiovascular disease presentation in type 2 diabetes: a large population-based cohort study. Frontiers in Endocrinology. 2024;15:1344007. DOI: 10.3389/fendo.2024.1344007
30. Östgren CJ, Merlo J, Råstam L, Lindblad U, for Skaraborg Hypertension and Diabetes Project. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes, Obesity and Metabolism. 2004;6(5):367–74. DOI: 10.1111/j.1462-8902.2004.00358.x
31. Choi J, Lee S, Choi E, Lee H, Han M, Ahn H-J et al. Accumulated hypertension burden on atrial fibrillation risk in diabetes mellitus: a nationwide population study. Cardiovascular Diabetology. 2023;22(1):12. DOI: 10.1186/s12933-023-01736-4
32. Arnautu D-A, Arnautu S-F, Tomescu M-C, Luca S, Luca C-T. Increased Left Atrial Stiffness is Significantly Associated with Paroxysmal Atrial Fibrillation in Diabetic Patients. Diabetes, Metabolic Syndrome and Obesity. 2023;16:2077–87. DOI: 10.2147/DMSO.S417675
33. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10):946–52. DOI: 10.1161/01.cir.98.10.946
34. O’Neal WT, Sandesara P, Hammadah M, Venkatesh S, Samman-Tahhan A, Kelli HM et al. Gender Differences in the Risk of Adverse Outcomes in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction. The American Journal of Cardiology. 2017;119(11):1785–90. DOI: 10.1016/j.amjcard.2017.02.045
35. Winters J, Isaacs A, Zeemering S, Kawczynski M, Maesen B, Maessen J et al. Heart Failure, Female Sex, and Atrial Fibrillation Are the Main Drivers of Human Atrial Cardiomyopathy: Results From the CATCH ME Consortium. Journal of the American Heart Association. 2023;12(22):e031220. DOI: 10.1161/JAHA.123.031220
36. Yoshida K, Obokata M, Kurosawa K, Sorimachi H, Kurabayashi M, Negishi K. Effect of Sex Differences on the Association Between Stroke Risk and Left Atrial Anatomy or Mechanics in Patients With Atrial Fibrillation. Circulation: Cardiovascular Imaging. 2016;9(10):e004999. DOI: 10.1161/CIRCIMAGING.116.004999
37. Chen Y-Z, Qiao S-B, Hu F-H, Yuan J-S, Yang W-X, Cui J-G et al. Left ventricular remodeling and fibrosis: Sex differences and relationship with diastolic function in hypertrophic cardiomyopathy. European Journal of Radiology. 2015;84(8):1487–92. DOI: 10.1016/j.ejrad.2015.04.026
38. Akoum N, Mahnkopf C, Kholmovski EG, Brachmann J, Marrouche NF. Age and sex differences in atrial fibrosis among patients with atrial fibrillation. EP Europace. 2018;20(7):1086–92. DOI: 10.1093/europace/eux260
39. Li Z, Wang Z, Yin Z, Zhang Y, Xue X, Han J et al. Gender differences in fibrosis remodeling in patients with long-standing persistent atrial fibrillation. Oncotarget. 2017;8(32):53714–29. DOI: 10.18632/oncotarget.16342
40. Patel D, Mohanty P, Di Biase L, Sanchez JE, Shaheen MH, Burkhardt JD et al. Outcomes and complications of catheter ablation for atrial fibrillation in females. Heart Rhythm. 2010;7(2):167–72. DOI: 10.1016/j.hrthm.2009.10.025
41. Dewan P, Rørth R, Jhund PS, Shen L, Raparelli V, Petrie MC et al. Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. Journal of the American College of Cardiology. 2019;73(1):29–40. DOI: 10.1016/j.jacc.2018.09.081
42. Dewan P, Rørth R, Raparelli V, Campbell RT, Shen L, Jhund PS et al. Sex-Related Differences in Heart Failure With Preserved Ejection Fraction. Circulation: Heart Failure. 2019;12(12):e006539. DOI: 10.1161/CIRCHEARTFAILURE.119.006539
43. Farooqui N, Killian JM, Smith J, Redfield MM, Dunlay SM. Advanced Heart Failure Characteristics and Outcomes in Women and Men. Journal of the American Heart Association. 2024;13(13):e033374. DOI: 10.1161/JAHA.123.033374
44. Hansen AL, Søndergaard MM, Hlatky MA, Vittinghof E, Nah G, Stefanick ML et al. Adverse Pregnancy Outcomes and Incident Heart Failure in the Women’s Health Initiative. JAMA Network Open. 2021;4(12):e2138071. DOI: 10.1001/jamanetworkopen.2021.38071
45. Keskin M, Avşar Ş, Hayıroğlu Mİ, Keskin T, Börklü EB, Kaya A et al. Relation of the Number of Parity to Left Ventricular Diastolic Function in Pregnancy. The American Journal of Cardiology. 2017;120(1):154–9. DOI: 10.1016/j.amjcard.2017.03.244
46. Kaur G, Lau E. Sex differences in heart failure with preserved ejection fraction: From traditional risk factors to sex-specific risk factors. Women’s Health. 2022;18:17455057221140209. DOI: 10.1177/17455057221140209
47. Stutsman N, Habecker B, Pavlovic N, Jurgens CY, Woodward WR, Lee CS et al. Sympathetic dysfunction is associated with worse fatigue and early and subtle symptoms in heart failure: an exploratory sex-stratified analysis. European Journal of Cardiovascular Nursing. 2024;23(5):532–9. DOI: 10.1093/eurjcn/zvad121
48. Da Silva LM, Coy‐Canguçu A, Paim LR, Bau AA, Nicolela Geraldo Martins C, Pinheiro S et al. Impaired Cardiac Sympathetic Activity Is Associated With Myocardial Remodeling and Established Biomarkers of Heart Failure. Journal of the American Heart Association. 2024;13(14):e035264. DOI: 10.1161/JAHA.124.035264
49. Sayegh ALC, Fan J, Vianna LC, Dawes M, Paton JFR, Fisher JP. Sex differences in the sympathetic neurocirculatory responses to chemoreflex activation. The Journal of Physiology. 2022;600(11):2669–89. DOI: 10.1113/JP282327
50. Yang X, Wen Y, Peng H, Zhu H, Wang WE, Zhou J. Gender Differences in Anxiety, Depression, Insomnia, and Quality of Life in Heart Failure With Preserved Ejection Fraction: A Multicenter, Cross-sectional Study. Journal of Cardiovascular Nursing. 2023;38(5):425–32. DOI: 10.1097/JCN.0000000000000951
51. Truby LK, O’Connor C, Fiuzat M, Stebbins A, Coles A, Patel CB et al. Sex Differences in Quality of Life and Clinical Outcomes in Patients With Advanced Heart Failure: Insights From the PAL-HF Trial. Circulation: Heart Failure. 2020;13(4):e006134. DOI: 10.1161/CIRCHEARTFAILURE.119.006134
52. Sugimoto T, Dulgheru R, Bernard A, Ilardi F, Contu L, Addetia K et al. Echocardiographic reference ranges for normal left ventricular 2D strain: results from the EACVI NORRE study. European Heart Journal -Cardiovascular Imaging. 2017;18(8):833–40. DOI: 10.1093/ehjci/jex140
53. Ministry of Health of Russian Federation. Clinical Recommendation. Chronic heart failure. 2024. Av. at: https://cr.minzdrav.gov.ru/schema/ 156_2.
54. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599–726. DOI: 10.1093/eurheartj/ehab368
55. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895–1032. DOI: 10.1161/CIR.0000000000001063
56. Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N et al. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European Journal of Heart Failure. 2019;21(6):715–31. DOI: 10.1002/ejhf.1494
57. Hildebrandt P, Collinson PO, Doughty RN, Fuat A, Gaze DC, Gustafsson F et al. Age-dependent values of N-terminal pro-Btype natriuretic peptide are superior to a single cut-point for ruling out suspected systolic dysfunction in primary care. European Heart Journal. 2010;31(15):1881–9. DOI: 10.1093/eurheartj/ehq163
58. Shetty NS, Patel N, Gaonkar M, Li P, Arora G, Arora P. Natriuretic Peptide Normative Levels and Deficiency. JACC: Heart Failure. 2024;12(1):50–63. DOI: 10.1016/j.jchf.2023.07.018
59. Aimo A, Januzzi JL, Vergaro G, Clerico A, Latini R, Meessen J et al. Revisiting the obesity paradox in heart failure: Per cent body fat as predictor of biomarkers and outcome. European Journal of Preventive Cardiology. 2019;26(16):1751–9. DOI: 10.1177/2047487319852809
60. Vergaro G, Gentile F, Meems LMG, Aimo A, Januzzi JL, Richards AM et al. NT-proBNP for Risk Prediction in Heart Failure: Identification of Optimal Cut offs Across Body Mass Index Categories. JACC: Heart Failure. 2021;9(9):653–63. DOI: 10.1016/j.jchf.2021.05.014
61. Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E et al. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal. 2019;40(40):3297–317. DOI: 10.1093/eurheartj/ehz641
62. Franke J, Lindmark A, Hochadel M, Zugck C, Koerner E, Keppler J et al. Gender aspects in clinical presentation and prognostication of chronic heart failure according to NT-proBNP and the Heart Failure Survival Score. Clinical Research in Cardiology. 2015;104(4):334–41. DOI: 10.1007/s00392-014-0786-z
63. Cesaroni G, Mureddu GF, Agabiti N, Mayer F, Stafoggia M, Forastiere F et al. Sex differences in factors associated with heart failure and diastolic left ventricular dysfunction: a cross-sectional population-based study. BMC Public Health. 2021;21(1):415. DOI: 10.1186/ s12889-021-10442-3
64. Willeit P, Kaptoge S, Welsh P, Butterworth AS, Chowdhury R, Spackman SA et al. Natriuretic peptides and integrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. The Lancet Diabetes & Endocrinology. 2016;4(10):840–9. DOI: 10.1016/S2213-8587(16)30196-6
65. Kim H-L, Kim M-A, Choi D-J, Han S, Jeon E-S, Cho M-C et al. Gender Difference in the Prognostic Value of N-Terminal Pro-B Type Natriuretic Peptide in Patients With Heart Failure - A Report From the Korean Heart Failure Registry (KorHF). Circulation Journal. 2017;81(9):1329–36. DOI: 10.1253/circj.CJ-16-1345
66. Rudolf H, Mügge A, Trampisch HJ, Scharnagl H, März W, Kara K. NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: The getABI-study. IJC Heart & Vasculature. 2020;29:100553. DOI: 10.1016/j.ijcha.2020.100553
67. Daubert MA, Yow E, Barnhart HX, Piña IL, Ahmad T, Leifer E et al. Differences in NT‐proBNP Response and Prognosis in Men and Women With Heart Failure With Reduced Ejection Fraction. Journal of the American Heart Association. 2021;10(10):e019712. DOI: 10.1161/JAHA.120.019712
68. Hamaguchi S, Kinugawa S, Sobirin MA, Goto D, Tsuchihashi-Makaya M, Yamada S et al. Mode of Death in Patients With Heart Failure and Reduced vs. Preserved Ejection Fraction: – Report From the Registry of Hospitalized Heart Failure Patients. Circulation Journal. 2012;76(7):1662–9. DOI: 10.1253/circj.CJ-11-1355
69. Cleland JGF, Bunting KV, Flather MD, Altman DG, Holmes J, Coats AJS et al. Beta-blockers for heart failure with reduced, midrange, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. European Heart Journal. 2018;39(1):26–35. DOI: 10.1093/eurheartj/ehx564
70. Mansur ADP, Del Carlo CH, Gonçalinho GHF, Avakian SD, Ribeiro LC, Ianni BM et al. Sex Differences in Heart Failure Mortality with Preserved, Mildly Reduced and Reduced Ejection Fraction: A Retrospective, Single-Center, Large-Cohort Study. International Journal of Environmental Research and Public Health. 2022;19(23):16171. DOI: 10.3390/ijerph192316171
71. Wang X, Vaduganathan M, Claggett BL, Hegde SM, Pabon M, Kulac IJ et al. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. Circulation. 2023;147(8):624–34. DOI: 10.1161/CIRCULATIONAHA.122.062832
72. Liu D, Hu K, Schregelmann L, Hammel C, Lengenfelder BD, Ertl G et al. Determinants of ejection fraction improvement in heart failure patients with reduced ejection fraction. ESC Heart Failure. 2023;10(2):1358–71. DOI: 10.1002/ehf2.14303
73. Lam CSP, McEntegart M, Claggett B, Liu J, Skali H, Lewis E et al. Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). European Journal of Heart Failure. 2015;17(3):301–12. DOI: 10.1002/ejhf.238
74. Wang X, Jering KS, Cikes M, Tokmakova MP, Mehran R, Han Y et al. Sex Differences in Clinical Characteristics and Outcomes After Myocardial Infarction With Low Ejection Fraction: Insights From PARADISE‐MI. Journal of the American Heart Association. 2023;12(17):e028942. DOI: 10.1161/JAHA.122.028942
75. López-Vilella R, Marqués-Sulé E, Laymito Quispe RDP, Sánchez-Lázaro I, Donoso Trenado V, Martínez Dolz L et al. The Female Sex Confers Different Prognosis in Heart Failure: Same Mortality but More Readmissions. Frontiers in Cardiovascular Medicine. 2021;8:618398. DOI: 10.3389/fcvm.2021.618398
76. Antwi-Amoabeng D, Neelam V, Ulanja MB, Beutler BD, Gbadebo TD, Sugathan P. Association between Psychiatric Disorders and the Incidence of Heart Failure in Women. Journal of Cardiovascular Development and Disease. 2023;10(12):491. DOI: 10.3390/jcdd10120491
77. Hamatani Y, Iguchi M, Ikeyama Y, Kunugida A, Ogawa M, Yasuda N et al. Prevalence, Temporal Change, and Determinants of Anxiety and Depression in Hospitalized Patients With Heart Failure. Journal of Cardiac Failure. 2022;28(2):181–90. DOI: 10.1016/j.cardfail.2021.07.024
78. Aguilar-Iglesias L, Perez-Asensio A, Vilches-Miguel L, Jimenez-Mendez C, Diez-Villanueva P, Perez-Rivera J-A. Impact of Frailty on Heart Failure Prognosis: Is Sex Relevant? Current Heart Failure Reports. 2024;21(2):131–8. DOI: 10.1007/s11897-024-00650-4
79. Díez-Villanueva P, Jiménez-Méndez C, López-Lluva MT, Wasniewski S, Solís J, Fernández-Friera L et al. Heart Failure in the Elderly: the Role of Biological and Sociocultural Aspects Related to Sex. Current Heart Failure Reports. 2023;20(5):321–32. DOI: 10.1007/s11897-023-00619-9
80. Son Y, Won MH. Gender differences in the impact of health literacy on hospital readmission among older heart failure patients: A prospective cohort study. Journal of Advanced Nursing. 2020;76(6):1345–54. DOI: 10.1111/jan.14328
81. Kawai A, Nagatomo Y, Yukino-Iwashita M, Nakazawa R, Yumita Y, Taruoka A et al. Sex Differences in Cardiac and Clinical Phenotypes and Their Relation to Outcomes in Patients with Heart Failure. Journal of Personalized Medicine. 2024;14(2):201. DOI: 10.3390/ jpm14020201
82. Garganeeva A.A., Tukish O.V., Vitt K.N., Mareev Yu.V., Kuzheleva E.A., Ryabov V.V. et al. Chronic Heart Failure in Patients Hospitalized in 2002 and 2021: Comparative Analysis of Prevalence, Clinical Course and Drug Therapy. Kardiologiia. 2024;64(3):3–10. DOI: 10.18087/cardio.2024.3.n2595
83. Shekelle PG, Rich MW, Morton SC, Atkinson ColSW, Tu W, Maglione M et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status. Journal of the American College of Cardiology. 2003;41(9):1529–38. DOI: 10.1016/S0735-1097(03)00262-6
84. Dewan P, Jackson A, Lam CSP, Pfeffer MA, Zannad F, Pitt B et al. Interactions between left ventricular ejection fraction, sex and effect of neurohumoral modulators in heart failure. European Journal of Heart Failure. 2020;22(5):898–901. DOI: 10.1002/ejhf.1776
85. Merrill M, Sweitzer NK, Lindenfeld J, Kao DP. Sex Differences in Outcomes and Responses to Spironolactone in Heart Failure With Preserved Ejection Fraction. JACC: Heart Failure. 2019;7(3):228–38. DOI: 10.1016/j.jchf.2019.01.003
86. Danielson C, Lileikyte G, Ouwerkerk W, S.P. Lam C, Erlinge D, Teng TK. Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta‐analysis. ESC Heart Failure. 2022;9(4):2753–61. DOI: 10.1002/ehf2.13974
87. McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR et al. Angiotensin–niprilysin Inhibition versus enalapril in heart failure. New England Journal of Medicine. 2014;371(11):993–1004. DOI: 10.1056/NEJMoa1409077
88. Curtain JP, Jackson AM, Shen L, Jhund PS, Docherty KF, Petrie MC et al. Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF. European Journal of Heart Failure. 2022;24(3):551–61. DOI: 10.1002/ejhf.2419
89. Liu X-H, Wang G-L, Xu Q, Zhang L, Liu H-J. Effect of sacubitril/valsartan on the occurrence of cardiac arrhythmias and the risk of sudden cardiac death in heart failure: A meta-analysis of randomized controlled trials. Frontiers in Cardiovascular Medicine. 2022;9:943377. DOI: 10.3389/fcvm.2022.943377
90. Tan NY, Sangaralingham LR, Sangaralingham SJ, Yao X, Shah ND, Dunlay SM. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure. 2020;8(1):43–54. DOI: 10.1016/j.jchf.2019.08.003
91. Basile C, Paolillo S, Gargiulo P, Marzano F, Asile G, Parlati ALM et al. Sacubitril/valsartan reduces cardiac decompensation in heart failure with preserved ejection fraction: a meta-analysis. Journal of Cardiovascular Medicine. 2023;24(1):44–51. DOI: 10.2459/JCM.0000000000001411
92. Solomon SD, McMurray JJV, Anand IS, Ge J, Lam CSP, Maggioni AP et al. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. New England Journal of Medicine. 2019;381(17):1609–20. DOI: 10.1056/NEJMoa1908655
93. McMurray JJV, Jackson AM, Lam CSP, Redfield MM, Anand IS, Ge J et al. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF. Circulation. 2020;141(5):338–51. DOI: 10.1161/CIRCULATIONAHA.119.044491
94. Young JB, Dunlap ME, Pfeffer MA, Probstfield JL, Cohen-Solal A, Dietz R et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110(17):2618–26. DOI: 10.1161/01.CIR.0000146819.43235.A9
95. St. Pierre SR, Peirlinck M, Kuhl E. Sex Matters: A Comprehensive Comparison of Female and Male Hearts. Frontiers in Physiology. 2022;13:831179. DOI: 10.3389/fphys.2022.831179
96. Novella S, Pérez‐Cremades D, Mompeón A, Hermenegildo C. Mechanisms underlying the influence of oestrogen on cardiovascular physiology in women. The Journal of Physiology. 2019;597(19):4873–86. DOI: 10.1113/JP278063
97. Rivasi G, Coscarelli A, Capacci M, Ceolin L, Turrin G, Tortù V et al. Tolerability of Antihypertensive Medications: The Influence of Age. High Blood Pressure & Cardiovascular Prevention. 2024;31(3):261–9. DOI: 10.1007/s40292-024-00639-z
98. Kostis WJ, Shetty M, Chowdhury YS, Kostis JB. ACE Inhibitor-Induced Angioedema: a Review. Current Hypertension Reports. 2018;20(7):55. DOI: 10.1007/s11906-018-0859-x
99. Sohani ZN, Behlouli H, De Moura CS, Abrahamowicz M, Pilote L. Sex Differences in the Effectiveness of Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Sacubitril–Valsartan for the Treatment of Heart Failure. Journal of the American Heart Association. 2023;12(14):e028865. DOI: 10.1161/JAHA.122.028865
100. Rossello X, Ferreira JP, Pocock SJ, McMurray JJV, Solomon SD, Lam CSP et al. Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials. European Journal of Heart Failure. 2020;22(5):834–44. DOI: 10.1002/ejhf.1740
101. Rossello X, Ariti C, Pocock SJ, Ferreira JP, Girerd N, McMurray JJV et al. Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials. Clinical Research in Cardiology. 2019;108(5):477–86. DOI: 10.1007/s00392-018-1378-0
102. Zaher W, Della Rocca DG, Pannone L, Boveda S, De Asmundis C, Chierchia G-B et al. Anti-Arrhythmic Effects of Heart Failure Guideline-Directed Medical Therapy and Their Role in the Prevention of Sudden Cardiac Death: From Beta-Blockers to Sodium-Glucose Cotransporter 2 Inhibitors and Beyond. Journal of Clinical Medicine. 2024;13(5):1316. DOI: 10.3390/jcm13051316
103. Kaddoura R, Madurasinghe V, Chapra A, Abushanab D, Al-Badriyeh D, Patel A. Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis. Current Problems in Cardiology. 2024;49(3):102376. DOI: 10.1016/j.cpcardiol.2024.102376
104. Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ et al. Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2021;143(4):326–36. DOI: 10.1161/CIRCULATIONAHA.120.051783
105. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine. 2019;381(21):1995–2008. DOI: 10.1056/NEJMoa1911303
106. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine. 2020;383(15):1413–24. DOI: 10.1056/NEJMoa2022190
107. Butt JH, Docherty KF, Petrie MC, Schou M, Kosiborod MN, O’Meara E et al. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial. JAMA Cardiology. 2021;6(6):678–89. DOI: 10.1001/jamacardio.2021.0379
108. Zannad F, Ferreira JP, Pocock SJ, Anker SD, Butler J, Filippatos G et al. SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. The Lancet. 2020;396(10254):819–29. DOI: 10.1016/S0140-6736(20)31824-9
109. Oates CP, Santos‐Gallego CG, Smith A, Basyal B, Moss N, Kawamura I et al. SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta‐analysis of randomized clinical trials. Journal of Cardiovascular Electrophysiology. 2023;34(5):1277–85. DOI: 10.1111/jce.15894
110. Xiang B, Zhang R, Wu X, Zhou X. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis. JAMA Network Open. 2022;5(9):e2231963. DOI: 10.1001/jamanetworkopen.2022.31963
111. Tang J, Wang P, Liu C, Peng J, Liu Y, Ma Q. Pharmacotherapy in patients with heart failure with reduced ejection fraction: A systematic review and meta-analysis. Chinese Medical Journal. 2024; [Ahead of print]. DOI: 10.1097/CM9.0000000000003118
112. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. The Lancet. 2008;372(9641):807–16. DOI: 10.1016/S0140-6736(08)61170-8
113. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. The Lancet. 2010;376(9744):875–85. DOI: 10.1016/S0140-6736(10)61198-1
114. Rathore SS, Wang Y, Krumholz HM. Sex-Based Differences in the Effect of Digoxin for the Treatment of Heart Failure. New England Journal of Medicine. 2002;347(18):1403–11. DOI: 10.1056/NEJMoa021266
115. Adams KF, Patterson JH, Gattis WA, O’Connor CM, Lee CR, Schwartz TA et al. Relationship of Serum Digoxin Concentration to Mortality and Morbidity in Women in the Digitalis Investigation Group Trial. Journal of the American College of Cardiology. 2005;46(3):497–504. DOI: 10.1016/j.jacc.2005.02.091
116. Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871–8. DOI: 10.1001/jama.289.7.871
117. Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW et al. Effects of Digoxin on Morbidity and Mortality in Diastolic Heart Failure: The Ancillary Digitalis Investigation Group Trial. Circulation. 2006;114(5):397–403. DOI: 10.1161/CIRCULATIONAHA.106.628347
118. Sica DA, Wood M, Hess M. Gender and Its Effect in Cardiovascular Pharmacotherapeutics: Recent Considerations. Congestive Heart Failure. 2005;11(3):163–6. DOI: 10.1111/j.1527-5299.2005.04171.x
119. Ahmed A, Pitt B, Rahimtoola SH, Waagstein F, White M, Love TE et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: A propensity-matched study of the DIG trial. International Journal of Cardiology. 2008;123(2):138–46. DOI: 10.1016/j.ijcard.2006.12.001
120. Celik A, Sahin A, Ata N, Colluoglu IT, Ural D, Kanik EA et al. Navigating Heart Failure: Unveiling Sex Disparities in Guideline-Directed Medical Therapy Combinations. The American Journal of Cardiology. 2024;216:27–34. DOI: 10.1016/j.amjcard.2024.01.017
121. Ouyang A-J, Lv Y-N, Zhong H-L, Wen J-H, Wei X-H, Peng H-W et al. Meta-Analysis of Digoxin Use and Risk of Mortality in Patients With Atrial Fibrillation. The American Journal of Cardiology. 2015;115(7):901–6. DOI: 10.1016/j.amjcard.2015.01.013
122. Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. European Heart Journal. 2015;36(28):1831–8. DOI: 10.1093/eurheartj/ehv143
123. Ziff OJ, Lane DA, Samra M, Griffith M, Kirchhof P, Lip GYH et al. Safety and efficacy of digoxin: systematic review and meta-analysis of observational and controlled trial data. BMJ. 2015;351:h4451. DOI: 10.1136/bmj.h4451
124. Bavishi C, Khan AR, Ather S. Digoxin in patients with atrial fibrillation and heart failure: A meta-analysis. International Journal of Cardiology. 2015;188:99–101. DOI: 10.1016/j.ijcard.2015.04.031
125. Dries DL, Rosenberg YD, Waclawiw MA, Domanski MJ. Ejection Fraction and Risk of Thromboembolic Events in Patients With Systolic Dysfunction and Sinus Rhythm: Evidence for Gender Differences in the Studies of Left Ventricular Dysfunction Trials. Journal of the American College of Cardiology. 1997;29(5):1074–80. DOI: 10.1016/S0735-1097(97)00019-3
126. Homma S, Thompson JLP, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. New England Journal of Medicine. 2012;366(20):1859–69. DOI: 10.1056/NEJMoa1202299
127. Mehra MR, Vaduganathan M, Fu M, Ferreira JP, Anker SD, Cleland JGF et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal. 2019;40(44):3593–602. DOI: 10.1093/eurheartj/ehz427
128. Beggs SAS, Rørth R, Gardner RS, McMurray JJV. Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. Heart. 2019;105(17):1325–34. DOI: 10.1136/heartjnl-2018-314381
129. Xie S, Chen J, Xiong G, Li J, Wan J, Liu Y et al. The efficacy and safety of rivaroxaban in coronary artery disease patients with heart failure and sinus rhythm: a systematic review and meta-analysis. European Journal of Clinical Pharmacology. 2021;77(10):1485–94. DOI: 10.1007/s00228-021-03195-w
130. Mareev V.Yu., Begrambekova Yu.L., Mareev Yu.V., Kobalava Zh.D., Karapetyan L.V., Galochkin S.A. et al. Iron deficiency in Russia heart failure patients. Observational cross-sectional multicenter study. Kardiologiia. 2022;62(5):4–8. DOI: 10.18087/cardio.2022.5.n2083
131. Begrambekova Yu.L., Mareev Yu.V., Mareev V.Yu., Orlova Ya.A., Kobalava Zh.D., Karapetyan L.V. et al. Female and Male Phenotypes of Iron Deficiency in CHF. Additional analysis of the “The Prevalence of Iron Deficiency in Patients With Chronic Heart Failure in the Russian Federation ( J-CHF-RF)” study. Kardiologiia. 2023;63(9):3–13. DOI: 10.18087/cardio.2023.9.n2413
132. McCullough PA, Barnard D, Clare R, Ellis SJ, Fleg JL, Fonarow GC et al. Anemia and Associated Clinical Outcomes in Patients With Heart Failure Due to Reduced Left Ventricular Systolic Function. Clinical Cardiology. 2013;36(10):611–20. DOI: 10.1002/clc.22181
133. Kajimoto K, Minami Y, Sato N, Otsubo S, Kasanuki H. Gender Differences in Anemia and Survival in Patients Hospitalized for Acute Decompensated Heart Failure With Preserved or Reduced Ejection Fraction. The American Journal of Cardiology. 2017;120(3):435–42. DOI: 10.1016/j.amjcard.2017.04.043
134. Anker SD, Khan MS, Butler J, Von Haehling S, Jankowska EA, Ponikowski P et al. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: A Bayesian meta‐analysis. European Journal of Heart Failure. 2023;25(7):1080–90. DOI: 10.1002/ejhf.2860
135. Ponikowski P, Mentz RJ, Hernandez AF, Butler J, Khan MS, Van Veldhuisen DJ et al. Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. European Heart Journal. 2023;44(48):5077–91. DOI: 10.1093/eurheartj/ehad586
136. Lam CSP, Piña IL, Zheng Y, Bonderman D, Pouleur A-C, Saldarriaga C et al. Age, Sex, and Outcomes in Heart Failure With Reduced EF: Insights From the VICTORIA Trial. JACC: Heart Failure. 2023;11(9):1246–57. DOI: 10.1016/j.jchf.2023.06.020
137. Bauersachs J, Arrigo M, Hilfiker-Kleiner D, Veltmann C, Coats AJS, Crespo-Leiro MG et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. European Journal of Heart Failure. 2016;18(9):1096–105. DOI: 10.1002/ejhf.586
138. Arany Z. Peripartum Cardiomyopathy. New England Journal of Medicine. 2024;390(2):154–64. DOI: 10.1056/NEJMra2306667 139. Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal. 2018;39(34):3165–241. DOI: 10.1093/eurheartj/ehy340
Review
For citations:
Glezer M.G. Chronic Heart Failure: Focus on Differences Between Men and Women. Kardiologiia. 2024;64(11):117-131. (In Russ.) https://doi.org/10.18087/cardio.2024.11.n2790
Views:
492
Email this article 
Post a Comment 
